Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.58 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30929767 | 0.88 | ERAP2 (0.58) | GHSRUTS2RKISS1RERAP2 | |
| SCHEMBL31171030 | 0.88 | GHSR (0.70) | GHSR | |
| SCHEMBL29874494 | 0.87 | ERAP2 (0.56) | GHSRUTS2RMMP2MMP9MMP8 | |
| SCHEMBL29684075 | 0.87 | ERAP2 (0.58) | GHSRKISS1RERAP2 | |
| SCHEMBL9112028 | 0.87 | UTS2R (0.62) | GHSRUTS2RKISS1R | |
| SCHEMBL31004373 | 0.86 | ERAP2 (0.61) | GHSRUTS2RERAP2 | |
| SCHEMBL30416193 | 0.86 | ECE1 (0.64) | GHSRERAP2 | |
| SCHEMBL29819949 | 0.86 | GHSR (0.62) | GHSRERAP2 | |
| SCHEMBL30788023 | 0.86 | ERAP2 (0.63) | GHSRMMP2MMP9MMP8MMP1 | |
| SCHEMBL30788015 | 0.85 | ERAP2 (0.59) | GHSRUTS2RMMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078144-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | WINKEY TECH USA INC (US) | 2026-03-19 | — | — | US | claimed |
| WO-2024217503-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | 深圳市维琪科技股份有限公司 | 2024-10-24 | — | — | WO | claimed |
| US-20260078144-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | WINKEY TECH USA INC (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2024217503-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | 深圳市维琪科技股份有限公司 | 2024-10-24 | — | — | WO | disclosed |
| CN-117343140-B | Active peptide, composition and use thereof | 深圳市维琪科技股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078144-A1 | ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF | ARGLU1, ARG1, POT1 | GHSR 372/4885UTS2R 3997/4885MMP2 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.